With a strong team of biopharmaceutical veterans and adequate funding, BioFront
aims to identify disease drivers and develop first-in-class therapeutics through
profit-sharing partnerships with academic investigators.
With a strong team of biopharmaceutical veterans and adequate funding, BioFront aims to identify disease drivers and develop first-in-class therapeutics through profit-sharing partnerships with academic investigators.
A well-recognized leader in pharmaceutical R&D with>20 years of management experience in pharma/biotech industry(Tularik,Amgen,Lilly). Inventor of 37 patents granted by the US Patent Office, including Amgen's PCSK9 antibody for the treatment of cardiovascular disease (Rapatha®).
30 years of pharmaceutical R&D experience, with broad expertise in inflammatory, immunological, metabolic and cardiovascular diseases. Contributor to 4 launched drugs (Singulair®, Arcoxia®, Vioxx®, Tredaptive®).
>20 years of medicinal chemistry experience in pharma/biotech industry (Lilly, PEG Bio) ; proven track record in leading cross-functional teams, managing CROs and delivering milestones for multiple projects. Contributed to the discovery of an HBV medicine Clevudine(Levovir®;).
30 years of R&D experience in metabolic diseases, immunology and oncology (3S Bio, Lilly, Pfizer). Led development of 2 marketed drugs.
国内做创新药的四大条件已逐渐成熟，原创新药已经天时地利人和。百放英库联合创始人、CEO单倍在论坛演讲中提出，创新药的大环境正在变化，在资本集结、科学人才资源的积累及海归潮、中…
2021年5月20日，百放英库实验大楼启用仪式在装潢一新宽敞明亮的大楼一楼隆重举行…
Our headquarters in Beijing is based in a newly constructed >4000m2 facility equipped with state-of-the-art chemistry and biology laboratory instruments, located in Zhongguancun Beilun Industrial Park, Haidian District.